Novo Nordisk, company announcement on the evoke and evoke+ trials of oral semaglutide in early Alzheimer’s disease (2025) (sponsor’s own announcement of a negative result)

Cited by name. No followable URL — the bibliographic record is the citation.

Authors. Novo Nordisk, company announcement on the

Venue. and evoke+ trials of oral semaglutide in early Alzheimer’s disease (sponsor’s own announcement of a negative result)

How the Institute flags it

established 1 time

Cited on 1 page

• Metabolic Medicines